Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors


The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer

Study Start Date

July 2015

Estimated Completion Date

February 2018


  • Drug: Nivolumab
  • Drug: Ulocuplumab


  • Internal Medicine: Clinical Pharmacology,Hematology/Oncology
  • Oncology: Pharmacology/Therapy
  • Pharmacy: Chemotherapy/Oncology

MeSH Terms

  • Nivolumab
  • Solid Tumors
  • Ulocuplumab

Study ID

Bristol-Myers Squibb -- CA212-115



Trial ID


Study Type


Trial Phase

Phase 1/Phase 2

Enrollment Quota



Bristol-Myers Squibb

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria

  • SCLC or PAC that is advanced or has spread to other parts of the body
  • Treated with at least one other chemotherapy that did not work or where cancer relapsed
  • Minimal limitations on activities of daily living as measured by Eastern Cooperative Oncology Group (ECOG) score of 0-1

Exclusion Criteria

  • Patients with cancer that spread to the brain
  • Active, known or suspected autoimmune disease
  • Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (6)

Study Location Distance Name Phone Email
Columbia University Medical Center Cumc - New York, New York 44.8 miles Naiyer Rizvi Site 0004 646-317-6344 None
Memorial Sloan Kettering Cancer Center - New York, New York 50.7 miles Eileen OReilly Site 0001 None None
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore, Maryland 219.6 miles Dung Le Site 0002 410-955-6795 None
Indiana University Health - Indianapolis, Indiana 686.4 miles Bert Oneil Site 0006 317-274-3150 None
University Of Colorado - Aurora, Colorado 1,658.2 miles Colin Weekes Site 0003 720-848-0643 None
Huntsman Cancer Institute - Salt Lake City, Utah 2,001.3 miles Ignacio GarridoLaguna Site 0005 801-587-4021 None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.